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Abstract
Background : The activity of dihydropyrimidine dehydrogenase (DPD), the key enzyme of
pyrimidine catabolism, is thought to be an important determinant for the occurrence of severe
toxic reactions to 5-fluorouracil (5-FU), which is one of the most commonly prescribed
chemotherapeutic agents for the treatment of solid cancers. Genetic variation in the DPD gene
(DPYD) has been proposed as a main factor for variation in DPD activity in the population.
However, only a small proportion of severe toxicities in 5-FU based chemotherapy can be
explained with such rare deleterious DPYD mutations resulting in severe enzyme deficiencies.
Recently, hypermethylation of the DPYD promoter region has been proposed as an alternative
mechanism for DPD deficiency and thus as a major cause of severe 5-FU toxicity.
Methods : Here, the prognostic significance of this epigenetic marker with respect to severe 5-
FU toxicity was assessed in 27 cancer patients receiving 5-FU based chemotherapy, including 17
patients experiencing severe toxic side effects following drug administration, none of which were
carriers of a known deleterious DPYD mutation, and ten control patients. The methylation status
of the DPYD promoter region in peripheral blood mononuclear cells was evaluated by analysing
for each patient between 19 and 30 different clones of a PCR-amplified 209 base pair fragment of
the bisulfite-modified DPYD promoter region. The fragments were sequenced to detect bisulfite-
induced, methylation-dependent sequence differences.
Results : No evidence of DPYD promoter methylation was observed in any of the investigated
patient samples, whereas in a control experiment, as little as 10% methylated genomic DNA could
be detected.
Conclusion : Our results indicate that DYPD promoter hypermethylation is not of major
importance as a prognostic factor for severe toxicity in 5-FU based chemotherapy.
Background
5-fluorouracil (5-FU) has been one of the most com-
monly prescribed chemotherapeutic agents in the treat-
ment of various types of cancer for over 40 years with
approximately two million patients treated worldwide
each year [1]. However, 10–30% of patients receiving the
drug develop a severe to life-threatening toxic reaction [2].
5-FU is a prodrug, thus requiring intracellular conversion
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into cytotoxic metabolites for anti-tumour effects to take
place and giving 5-FU metabolising enzymes a crucial role
in determining the effect of the drug [1]. Since about 85%
of the administered dose of 5-FU are usually rapidly elim-
inated, the catabolic pathway, and its key enzyme dihy-
dropyrimidine dehydrogenase (DPD), are particularly
important in determining a patient's response to 5-FU [3].
DPD activity is highly variable in the population, with an
estimated proportion of 3–5% of individuals showing
low or deficient DPD activity [4], which is thought to
result in an increased half-life of 5-FU and therefore an
increased risk of toxicity [1]. Part of this variability is
explained by genetic variation in the DPD gene (DPYD),
where over 40 polymorphisms have been described so far.
Several of these gene variants have been associated with
reduced enzyme activity and severe toxic side effects to 5-
FU [1,5-9], the most prominent being a point mutation in
the splice site of intron 14 (IVS14+1G>A) resulting in the
deletion of exon 14 and thus a non-functional enzyme
[10,11]. However, the clinical consequences of this and
other mutations in the DPD gene remain unclear, and a
large proportion of the observed variation in DPD activity
is still unexplained. Recently, partial methylation of the
DPYD promoter region has been suggested as an alterna-
tive mechanism for DPD deficiency and thus also as a
basis for 5-FU toxicity [12]. More specifically, in this
study, patients and healthy volunteers with low DPD
activity displayed a partially methylated DPYD promoter
region, whereas no methylation was detected in individu-
als with normal enzyme activity. Most interestingly, par-
tial DPYD promoter methylation was observed in all DPD
deficient individuals not carrying any known inactivating
DPYD mutation. These results thus strongly indicated that
this epigenetic mechanism might be an important deter-
minant of DPD activity.
Previously [13], we screened the entire coding region of
DPYD in 111 cancer patients receiving 5-FU based chem-
otherapy, including 24 patients with severe toxic side
effects (NCI CTCAE grade ≥ 3). However, none of the
patients experiencing severe adverse reactions were carri-
ers of a mutation, which has previously been associated
with low DPD activity or severe 5-FU toxicity. On the con-
trary, some of these gene variants, including the
IVS14+1G>A splice site mutation, were detected in
patients with no or only mild side effects. Since none of
the observed grade ≥ 3 toxicities could be explained by
known deleterious DPYD mutations in this study popula-
tion, we aimed at investigating a potential epigenetic
effect in the same patients. In the present study, we there-
fore assessed the methylation status of the DPYD pro-
moter region in a subsample of this study population, in
order to determine the prognostic significance of this epi-
genetic marker with respect to severe 5-FU toxicity.
The investigated gene region was a 209 base pair fragment
of the 5' untranslated region of DPYD, the same region as
investigated in [12]. This fragment contains 27 CpG sites,
eleven of which are located within two sequence elements
(shown in Figure 1), which have previously been reported
to be of regulatory importance [14]. CpG methylation in
this region was assessed in peripheral blood mononuclear
cells by bisulfite modification (BSM) of genomic DNA,
PCR amplification of the specified gene region using
methylation-independent primers, and cloning of ampli-
fied fragments. Since partial methylation, as it was
observed in the previous study [12], would result in a mix-
ture of methylated and unmethylated DNA copies, the
cloning procedure enabled us to separately sequence indi-
vidual amplified fragments, and thus estimate the propor-
tion of methylated DNA in the sample.
Methods
Patients
A total of 27 patients were investigated, including 17
patients experiencing severe toxicity following fluoropyri-
midine treatment, and ten randomly selected control
patients who did not develop any or only a mild to mod-
erate toxic reaction (Table 1). All patients suffered from
solid malignant tumors and were treated with various
chemotherapy regimens including monotherapies with 5-
FU or capecitabine, and combinations with other cyto-
toxic drugs (Table 1). None of the analysed patients with
severe toxic side effects were carriers of a known deleteri-
ous DPYD mutation (Table 1), and all non-synonymous
mutations detected in these patients were previously
observed at similar frequencies also in patients without
severe toxic reaction [15]. Blood samples were collected
before or during chemotherapy after getting informed
consent from all patients; adverse drug effects during the
first and second course of chemotherapy were assessed by
detailed chart review, and were classified according to the
Common Terminology Criteria for Adverse Events
(CTCAE) v3.0 [16]. All toxicities equal to or greater than
grade three were considered severe.
Bisulfite modification and PCR amplification of the DPYD 
promoter region
Genomic DNA was extracted from EDTA-blood samples
using the BioRobot EZ1 (Qiagen) and the EZ1 DNA blood
350 μl Kit (Qiagen). Up to 2 μg of genomic DNA were
subsequently bisulfite-modified (BSM) using the EpiTect
Bisulfite Kit (Qiagen) according to the instructions pro-
vided by the manufacturer. A 209 bp fragment of the
DPYD promoter region was amplified from BSM samples
using a GeneAmp 9700 Thermal Cycler (Applied Biosys-
tems) and the same primers as described in [12]. The 25
μl PCR volume contained 1 μl of BSM DNA, 1 μl of each
primer (10 μM), 1 μl of dNTP (10 mM each), 3 μl of
MgCl2 solution (25 mM), 2.5 μl of AmpliTaq Gold BufferJournal of Experimental & Clinical Cancer Research 2008, 27:54 http://www.jeccr.com/content/27/1/54
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and 0.5 μl of AmpliTaq Gold DNA polymerase (Applied
Biosystems). The following reaction conditions were
used: denaturation at 96°C for 10 min, followed by 40
cycles of 50 s at 96°C, 50 s at 52°C, and 1 min at 72°C,
and a final extension step at 72°C for 10 min. PCR prod-
ucts were subsequently re-amplified for cloning using
either1 μl of undiluted PCR product (if PCR band was not
visible or very weak after first amplification) or 1 μl of
PCR product diluted 1:100 (if PCR band from first ampli-
fication was clearly visible) using touchdown PCR. If
amplification with a proofreading polymerase was
required for the cloning step (StabyCloning kit), this
reamplification step was performed using 0.5 μl of Accu-
prime GC-rich polymerase (Invitrogen) with 5 μl of the
provided 5× buffer, and 0.5 μl of each primer (10 μM) in
a 25 μl reaction volume. Otherwise, the same reaction mix
as described above was used. The reaction conditions for
the touchdown PCR were the following: an initial dena-
turation step of 10 min at 95°C was followed by five times
two cycles with annealing temperatures lowered gradually
from 62°C to 54°C in steps of 2°C with 50 s at 94°C, 50
s at the respective annealing temperature, and 1 min at
72°C. This touchdown step was followed by 20 cycles
with 50 s at 94°C, 50 s at 52°C, and 1 min at 72°C, and
a final extension step of 10 min at 72°C.
Cloning and sequence analysis
After purification using the QIAquick PCR Purification Kit
(Qiagen), PCR products were cloned using the StabyClon-
ing kit (Eurogentec) or the QIAGEN PCR cloning kit (Qia-
gen) according to the instructions given by the
manufacturer. For each sample analysed, a total of 19 to
30 different colonies (Table 1) containing the correct
insert were amplified using AmpliTaq Gold DNA
BSM induced, methylation-specific sequence differences in the DPYD promoter region Figure 1
BSM induced, methylation-specific sequence differences in the DPYD promoter region. Sequence chromatograms 
of clone inserts originating from methylated and unmethlyated DNA, obtained in the control experiment using enzymatically 
methylated DNA. Unmethylated cytosines at CpG sites (indicated with black arrows) are converted to thymines, resulting in a 
sequence change. The two regulatory elements are shown; numbers indicate the sequence position relative to the transcrip-
tion start site.Journal of Experimental & Clinical Cancer Research 2008, 27:54 http://www.jeccr.com/content/27/1/54
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polymerase (Applied Biosystems) in the same reaction
mix as described above and the primers provided by the
manufacturer for the Staby Cloning kit, or T7 and M13 for
the QIAGEN PCR cloning kit, respectively. Amplified
inserts were subsequently sequenced using the same prim-
ers, the Big Dye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems) and an ABI Prism 3130xl Genetic
Analyzer (Applied Biosystems). The obtained sequences
were analysed for methylation-specific, bisulfite-induced
sequence changes using the software Sequencher v.4.7
(Gene Codes Corporation).
Enzymatic methylation of genomic DNA
To exclude a potential amplification bias during PCR
amplification and to establish the detection limit of the
cloning procedure, a control experiment was conducted
using various amounts of enzymatically methylated
genomic DNA. For enzymatic methylation, genomic DNA
Table 1: Clinical data of investigated patients, DPYD genotype and number of clones sequenced per patient.
Toxicity grade N clones
Sex Age Tumor Regimen hematologic gastrointestinal dermatologic DPYD genotype 
(coding region/splice sites)
Total Methylated
Patients with severe 5-FU related toxicity
1 m 53 Gastric 5FU-FA 1 3 0 - 21 0
2 f 70 Breast CAPE 0 3 0 c.85T>C, C29R; c.496A>G, 
M166V
20 0
3 f 55 Gastric CAPE-P 3 0 0 c.1601G>A, S534N 21 0
4 m 74 Colon 5FU-FA-P 4 4 0 - 20 0
5 f 53 Colon 5FU-FA-P 3 1 0 c.496A>G, M166V 21 0
6 m 66 Tonsil 5FU-P 2 3 3 c.85T>C, C29R; 1236G>A, E412E 20 0
7 m 53 Oesophagus 5FU-P 4 4 0 - 20 0
8 f 54 Breast E-5FU-C 3 1 0 1627A>G, I543V 21 0
9 f 65 Gastric E-5FU-P 3 1 2 - 22 0
10 m 79 Oesophagus 5FU-P 2 3 0 c.85T>C, C29R; c.1236G>A, 
E412E
20 0
11 f 67 Rectum 5FU-P 4 4 0 c.496A>G, M166V 22 0
12 f 57 Gastric E-5FU-P 3 1 0 c.85T>C, C29R; c.1236G>A, 
E412E; c.1627A>G, I543V
20 0
13 m 57 Rectum 5FU 3 0 0 1896T>C, F632F 21 0
14 m 67 unknowna 5FU-IRI 3 0 0 c.85T>C, C29R; c.1627A>G, 
I543V
24 0
15 f 50 Rectum 5FU-FA-P 1 3 0 c.85T>C, C29R 25 0
16 m 75 Gastric 5FU 2 3 0 - 21 0
17 f 47 Breast CAPE 1 1 3 c.85T>C, C29R; c.496A>G, 
M166V
30 0
Control patients
18 f 72 Rectum 5FU 1 1 0 - 20 0
19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T>G, I560S 21 0
20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T>C, C29R; c.1627A>G, 
I543V(H)
20 0
21 m 62 Colon 5FU-FA-P 0 1 0 c.85T>C, C29R (H); c.496A>G, 
M166V, c.1236G>A, E412E
19 0
22 f 64 Colon 5FU-FA 0 0 0 c.85T>C, C29R; c.1627A>G, 
I543V
20 0
23 m 63 Oesophagus 5FU-P 1 0 0 - 20 0
24 f 69 Colon 5FU-FA 0 1 0 c.85T>C, C29R (H); c.496A>G, 
M166V; c.2194G>A, V732I
20 0
25 m 59 Gastric 5FU-FA 1 1 0 c.85T>C, C29R; c.1627A>G, 
I543V; 1896T>C, F632F
21 0
26 m 59 Colon 5FU-FA-P 1 1 0 c.85T>C, C29R (H); c.496A>G, 
M166V; c.1627A>G, I543V
20 0
27 m 62 Gastric E-CAPE-P 2 1 2 c.85T>C, C29R (H); c.496A>G, 
M166V; c.1236G>A, E412E 
c.1627A>G, I543V
30 0
Abbreviations: FA, folinic acid; CAPE, capecitabine; P, platinum compound; E, epirubicin; C, cyclophosphamide; H, homozygous carrier a 
adenocarcinoma of unknown originJournal of Experimental & Clinical Cancer Research 2008, 27:54 http://www.jeccr.com/content/27/1/54
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from two randomly selected patients was methylated
using CpG Methylase M.SssI (New England BioLabs).
Approximately 1 μg of DNA was incubated for two hours
at 37°C with 1 μl of SssI, 5 μl of NEBuffer 2 (New England
BioLabs) and 5 μl of S-adenosylmethionine (1.6 mM) in
a reaction volume of 50 μl, followed by an inactivation
step of 20 min at 65°C. Reactions were subsequently puri-
fied using standard phenol-chloroform purification, fol-
lowed by ethanol precipitation. The precipitated DNA was
resolved in 15 μl of the same elution buffer as used for the
isolation of genomic DNA from patient samples. The two
methylated DNA samples were subsequently pooled and
mixed with BSM genomic DNA from an unmethylated
patient sample to contain 10%, 20%, 50% and 100%
methlyated BSM DNA, and subjected to the same proce-
dure as described for the patient samples.
Results and discussion
No evidence of DPYD promoter methylation was
observed in any of the 17 investigated patients experienc-
ing severe 5-FU toxicity. Also in the ten control patients,
no indication for DPYD promoter methylation was found
(Table 1). More specifically, in all of the 19 to 30 cloned
fragments analysed per patient, a majority (mean: 98%;
range: 81% – 100%) of the 27 CpG sites showed BSM-
induced conversions of cytosines to thymines, indicative
of unmethlyated cytosines (as shown in Figure 1). On the
other hand, increasing numbers of clones containing
methylated gene copies, indicated by the preservation of
cytosines in the sequence (Figure 1), were detected in the
control experiment, according to the amount of enzymat-
ically methylated DNA added. In the fragments consid-
ered as showing methylation, on average, 90% of the CpG
sites were methylated (range: 41 – 100%). In the sample
containing 100% methylated DNA, 18 out of 22 analysed
clones contained methylation-specific sequences (82%),
indicating an efficiency of the enzymatic methylation of
about 80%. One methylated gene copy was detected also
in the sample containing only 10% methylated BSM DNA
(one out of 20 analysed clones). In the samples contain-
ing 20% and 50% methylated DNA, intermediate num-
bers of methylated clones were observed (five out of 21
and five out of 20 clones, respectively). Therefore, we con-
cluded that as little as 10% methylation of the DPYD pro-
moter region should be detectable using the above-
described procedure. Also, the results of this control
experiment showed no indication for an amplification
bias towards unmethylated gene copies.
The occurrence of severe 5-FU related toxicity in the 17
investigated patients was thus not explained by an epige-
netic regulation of the DPYD promoter region. Our find-
ings are in agreement with an other recent study, where no
evidence for DPYD promoter methylation was detected in
28 patients with grade 4 toxicity following 5-FU adminis-
tration [15]. To our knowledge, only the study mentioned
above and our own have investigated the predictive
potential of DPYD promoter methylation in larger sam-
ples of 5-FU treated patients, and both studies did not
detect any evidence for such an epigenetic downregula-
tion of DPD. However, although no study so far was able
to confirm the initial findings by [12], which were based
on a very small sample size, various studies nevertheless
suggest epigenetic factors as an alternative explanation for
the occurrence of severe 5-FU toxicity where no other
molecular basis was found in DPYD [17-19].
Therefore, it is important to recognise that our results and
those by [15] strongly indicate that DPYD promoter
methylation is, if at all, only of minor importance as a pre-
dictive factor for severe toxic side effects in 5-FU based
chemotherapy. The molecular basis of severe 5-FU toxicity
can thus currently not be attributed to known genetic or
epigenetic factors in the DPD gene for a majority of the
observed cases in this and other studies [15,17,20].
Whereas it can not be excluded that other, yet unknown
genetic or epigenetic factors resulting in a reduced DPD
activity may be of value for the prediction of 5-FU toxicity,
also various polymorphisms in genes other than DPYD
have recently been shown to be correlated with the occur-
rence of severe adverse side effects to 5-FU [21-23]. A
promising approach for future investigations could there-
fore be to expand the focus from investigating isolated
genes like DPYD to a more comprehensive view of taking
into account genetic variation in the entire biological
pathway [24]. Hopefully, such combinatory approaches
will finally lead to results, which are both reproducible
and translatable into the clinic.
Conclusion
Our results indicate that DYPD promoter hypermethyla-
tion is not of major importance as a prognostic factor for
severe toxicity in 5-FU based chemotherapy.
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